Andrés Felipe Aristizábal-Pachón1, Thais Inácio de Carvalho2, Helio Humberto Angotti Carrara3, Jurandyr Moreira de Andrade3, Catarina Satie Takahashi4. 1. Department of Genetics, Ribeirão Preto Medical School, University of São Paulo, Bloco G., Avenue Bandeirantes, 3900, 14049-900 Ribeirão Preto, SP, Brazil. Electronic address: afaristizabal@usp.br. 2. Department of Oncology, Hospital Santa Casa of Ribeirão Preto, Avenue Saudade, 356, 14085-000 Ribeirão Preto, SP, Brazil. 3. Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, 14049-900 Ribeirão Preto, SP, Brazil. 4. Department of Genetics, Ribeirão Preto Medical School, University of São Paulo, Bloco G., Avenue Bandeirantes, 3900, 14049-900 Ribeirão Preto, SP, Brazil; Department of Biology, Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, 14040-901 Ribeirão Preto, SP, Brazil.
Abstract
BACKGROUND: Mammaglobin A (MGA), mainly expressed in the breast epithelium, is overexpressed in breast cancer, and has been established as a tumor and promissory marker for the early detection of metastasis. AIM: The main aim of this study was to evaluate the association between the presence of the MGA transcript in the peripheral blood of Brazilian breast cancer patients and healthy women and the development of breast cancer and tumor progression. MATERIAL AND METHODS: The expression of the MGA transcript in peripheral blood of 102 breast cancer patients and 102 healthy women was assessed by RT-PCR. RESULTS: MGA mRNA was expressed in the peripheral blood of 39 breast cancer patients and in none of the women from the control group. The presence of MGA was significantly associated with presence of metastasis and age at onset after 60 years. The presence of MGA mRNA in peripheral blood displayed a sensitivity of 38.2%, specificity of 100.0%, positive predictive value (PPV) of 100.0%, and negative predictive value (NPV) of 61.8% as a breast cancer marker. CONCLUSION: This study provides additional evidence of the presence of MGA in the peripheral blood of breast cancer patients, and its applicability as an efficient biomarker for breast cancer (High specificity and PPV). To our knowledge, this is the first study to assess the expression of MGA mRNA in peripheral blood obtained from the Brazilian population.
BACKGROUND:Mammaglobin A (MGA), mainly expressed in the breast epithelium, is overexpressed in breast cancer, and has been established as a tumor and promissory marker for the early detection of metastasis. AIM: The main aim of this study was to evaluate the association between the presence of the MGA transcript in the peripheral blood of Brazilian breast cancerpatients and healthy women and the development of breast cancer and tumor progression. MATERIAL AND METHODS: The expression of the MGA transcript in peripheral blood of 102 breast cancerpatients and 102 healthy women was assessed by RT-PCR. RESULTS:MGA mRNA was expressed in the peripheral blood of 39 breast cancerpatients and in none of the women from the control group. The presence of MGA was significantly associated with presence of metastasis and age at onset after 60 years. The presence of MGA mRNA in peripheral blood displayed a sensitivity of 38.2%, specificity of 100.0%, positive predictive value (PPV) of 100.0%, and negative predictive value (NPV) of 61.8% as a breast cancer marker. CONCLUSION: This study provides additional evidence of the presence of MGA in the peripheral blood of breast cancerpatients, and its applicability as an efficient biomarker for breast cancer (High specificity and PPV). To our knowledge, this is the first study to assess the expression of MGA mRNA in peripheral blood obtained from the Brazilian population.
Authors: Andres Felipe Aristizabal-Pachon; Yeimy Gonzalez-Giraldo; Angela Yazmin Garcia; Dalia Xiomara Suarez; Angela Rodriguez; Janneth Gonzalez-Santos Journal: Asian Pac J Cancer Prev Date: 2022-01-01
Authors: Abhilasha Sinha; Bibbin T Paul; Lisa M Sullivan; Hillary Sims; Ahmed El Bastawisy; Hend F Yousef; Abdel-Rahman N Zekri; Abeer A Bahnassy; Wael M ElShamy Journal: Oncotarget Date: 2017-02-07